Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 9/20 | 0.46 |
| ▸ | MAPT | P10636 | 8/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.46 |
| ▸ | HPGD | P15428 | 4/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31456048 | 0.84 | MTNR1A (0.48) | L3MBTL1MAPTTDP1HPGDNPC1 | |
| SCHEMBL2497117 | 0.84 | L3MBTL1 (0.51) | L3MBTL1MAPTTDP1HPGDNPC1 | |
| SCHEMBL3720086 | 0.84 | L3MBTL1 (0.47) | L3MBTL1MAPTTDP1HPGDNPC1 | |
| SCHEMBL31583912 | 0.81 | PTPN1 (0.49) | L3MBTL1MAPTTDP1HPGDNPC1 | |
| SCHEMBL17260308 | 0.79 | MAPT (0.50) | L3MBTL1MAPTTDP1HPGDNPC1 | |
| SCHEMBL15730490 | 0.79 | HTR7 (0.60) | L3MBTL1MAPTTDP1HPGDNPC1 | |
| SCHEMBL31648415 | 0.79 | L3MBTL1 (0.46) | L3MBTL1MAPTTDP1HPGDNPC1 | |
| SCHEMBL14968907 | 0.79 | L3MBTL1 (0.50) | L3MBTL1MAPTTDP1HPGDNPC1 | |
| SCHEMBL8702633 | 0.78 | MAPT (0.54) | L3MBTL1MAPTTDP1HPGDNPC1 | |
| SCHEMBL9544160 | 0.78 | L3MBTL1 (0.44) | L3MBTL1MAPTSMN1; SMN2LMNACA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0841925-B1 | ENDOTHELIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2006-10-04 | — | — | EP | disclosed |
| US-6482956-B2 | FOR THERAPY OF CARDIOVASCULAR, CEREBROVASCULAR, RESPIRATORY AND RENAL DISORDERS | SMITHKLINE BEECHAM CORPORATION | 2002-11-19 | — | — | US | disclosed |
| US-20020072614-A1 | Endothelin receptor antagonists | LUENGO JUAN IGNACIO (US) | 2002-06-13 | — | — | US | disclosed |
| US-6353116-B1 | Endothelin receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2002-03-05 | — | — | US | disclosed |
| EP-0841925-A4 | ENDOTHELIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2001-10-17 | — | — | EP | disclosed |
| US-6096897-A | NOVEL 1,2,3-TRIAZOLES | SMITHKLINE BEECHAM CORPORATION (US) | 2000-08-01 | — | — | US | disclosed |
| US-5969151-A | PYRAZOLE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-10-19 | — | — | US | disclosed |
| US-5958968-A | CARDIOVASCULAR DISORDERS; KIDNEY DIEASES | SMITHKLINE BEECHAM CORPORATION (US) | 1999-09-28 | — | — | US | disclosed |
| CN-1196680-A | Endothelin receptor antagonists | SMITHKLINE BEECHAM CORP (US) | 1998-10-21 | — | — | CN | disclosed |
| EP-0841925-A1 | ENDOTHELIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-05-20 | — | — | EP | disclosed |
| WO-1997004772-A1 | ENDOTHELIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020072614-A1 | Endothelin receptor antagonists | EDNRA, EDNRB, ECE1 | L3MBTL1 4835/4885MAPT 3139/4885TDP1 842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.